| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 16, 2019FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons
DUBLIN - May 16, 2019 - Medtronic plc (NYSE:MDT), a global leader in percutaneous coronary intervention (PCI) innovation, today announced its entrance into the guide extension catheter market with...
-
Feb 26, 2019FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTO
DUBLIN - February 26, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute...
-
Nov 8, 2018FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension
DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal...
-
Sep 21, 2018TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES
DUBLIN and SAN DIEGO - September 22, 2018 - Investigators today unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500...
-
May 24, 2018Onyx 1-Month OCT Study Provides Potential Insights on DAPT Duration in Complex Patients Following Stent Implantation
DUBLIN and PARIS- May 24, 2018 - Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that...